Gastrointestinal adverse events after dual Antiplatelet therapy: Clopidogrel is safer than Ticagrelor, but Prasugrel data are lacking or inconclusive

Victor L. Serebruany, James J. Dinicolantonio, Mehmet Mustafa Can, Igor V. Pershukov, Wiktor Kuliczkowski

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Current guidelines offer a choice of P2Y12 receptor antagonist among clopidogrel, prasugrel or ticagrelor on top of aspirin (ASA) for dual antiplatelet therapy (DAPT) in patients after acute coronary syndromes (ACS). However, the comparative risks of gastrointestinal (GI) adverse events during DAPT are not clear. Two large ACS trials (TRITON and PLATO) provide a valuable opportunity to directly match the risks of GI complications among current antiplatelet regimens. We compared the rates of GI adverse events after prasugrel and ticagrelor versus clopidogrel based on the Food and Drug Administration (FDA) clinical safety reviews. When compared with ticagrelor, clopidogrel is safer with regard to GI-related risks including fewer overall GI/anal bleeding events and spontaneous GI hemorrhagic episodes, less nausea, vomiting, dyspepsia and diarrhea, and a lower rate of presence of Helicobacter pylori. Among GI symptoms, only constipation was more common after clopidogrel than following ticagrelor. There were extrahepatic risks observed with ticagrelor but not with prasugrel when compared to clopidogrel. Prasugrel unquestionably caused more bleeding from the GI tract and GI malignancies than clopidogrel. However, the entire spectrum of GI effects of prasugrel is much less well known and mostly based on sponsor analysis rather than FDA-verified numbers. Among 3 DAPT options on top of ASA, clopidogrel seems to represent the safest alternative, although comprehensive data on direct prasugrel-associated GI effects are lacking or inconclusive.

Original languageEnglish (US)
Pages (from-to)35-40
Number of pages6
Issue number1
StatePublished - Aug 2013


  • Adverse events
  • Aspirin
  • Bleeding
  • Clopidogrel
  • Dual antiplatelet therapy
  • Gastrointestinal complications
  • Hemorrhagic events
  • Prasugrel
  • Ticagrelor

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)


Dive into the research topics of 'Gastrointestinal adverse events after dual Antiplatelet therapy: Clopidogrel is safer than Ticagrelor, but Prasugrel data are lacking or inconclusive'. Together they form a unique fingerprint.

Cite this